Clinical trial Recruiting at 1 site Interventional Ages 18 to 50 Women only

Radiofrequency combined with ultrasound for postpartum sexual pain

Official title: Effectiveness of Combined Monopolar Radiofrequency and Ultrasound (BTL EXILIS ULTRA 360™) for the Improvement of Dyspareunia Caused by Postpartum Scarring in Women of Childbearing Age: A Study Protoco

Run by Institut Investigacio Sanitaria Pere Virgili · NCT07504991 · Data updated 2026-11-12

This study will try a combined radiofrequency and ultrasound treatment (BTL Exilis) to reduce pain during sex in women who developed dyspareunia after a vaginal delivery.

More Dyspareunia trials

Quick facts

Study typeInterventional
Ages18 Years to 50 Years
SexWomen only
Enrollment34 (estimated)
SponsorInstitut Investigacio Sanitaria Pere Virgili
Academic / other
Locations1 site (Tarragona, TARRAGONA)
StatusRecruiting
StartedApril 2026
Main results expectedJuly 1, 2026
Study endsDecember 2026
Registry record updatedApril 16, 2026
Trial IDNCT07504991 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women of childbearing age with at least one prior vaginal delivery involving a tear or episiotomy, persistent moderate-to-severe dyspareunia (VAS ≥4), and no contraindications to radiofrequency/ultrasound are ideal candidates.

Probably not a fit

Patients with non-postpartum causes of dyspareunia, mild pain (VAS <4), underlying pelvic pathology causing pain, or medical contraindications to the device are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a community-based, non-randomized, quasi-experimental study delivering monopolar radiofrequency combined with ultrasound (BTL Exilis) to women with dyspareunia following at least one vaginal delivery that involved a tear or episiotomy. Pain during penetrative intercourse will be measured before and after treatment in the same individuals using the Visual Analogue Scale (VAS), with moderate-to-severe pain defined as VAS ≥4. There is no randomized control group; the primary outcome is resolution or reduction of pain during sexual intercourse after completing the treatment. The trial is conducted at Centro Procrear in Tarragona and requires informed consent and clinical confirmation of postpartum dyspareunia.

Why it matters

Potential benefit: If successful, the treatment could reduce or eliminate pain during intercourse and improve sexual function and quality of life for affected women.

How similar studies have gone: Energy-based vaginal therapies including radiofrequency have been used for vaginal laxity and sexual symptoms with mixed and limited high-quality evidence, and specific data for postpartum dyspareunia are sparse.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women of childbearing age
* Medical history of at least one prior vaginal delivery
* Reported persistent pain during penetrative sexual intercourse
* Meeting the clinical criteria for dyspareunia
* Moderate to severe pain level, defined as a score of 4 or higher on the Visual Analogue Scale (VAS 0-10)
* Eligible patients must demonstrate a moderate to severe pain level, defined as a VAS score of 4 or higher
* No restriction on the time elapsed between the last delivery and the current clinical diagnosis.

Exclusion Criteria:

* Contraindications to the study treatment. Women with any medical condition that precludes the use of the study technology
* Non-postpartum dyspareunia

Where it's running

  • Centro Procrear
    Tarragona, Tarragona, Spain
    Recruiting

Study contacts

  • Principal investigator: Lys Garcia Vilaplana, Midwife. Phd Student — Universitat Rovira I Virgili. Procrear Medical Center
  • Study coordinator: LYS GARCIA VILAPLANA, Lead Researcher
  • Email: lys@procrear.es
  • Phone: +34619357158

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.